AGP
REGN icon

Aspire Growth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Aspire Growth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
643
+17
+3% +$11.6K 0.23% 81
2026
Q1 		$484K Hold
626
– – 0.33% 68
2025
Q4 		$483K Buy
626
+1
+0.2% +$679 0.34% 69
2025
Q3 		$351K Buy
625
+1
+0.2% +$565 0.26% 85
2025
Q2 		$328K Buy
624
+1
+0.2% +$558 0.27% 86
2025
Q1 		$349K Buy
623
+32
+5% +$22K 0.31% 77
2024
Q4 		$421K Buy
+591
New +$496K 0.41% 61

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Aspire Growth Partners's REGN Position: Q2 2026 in Review

Aspire Growth Partners increased its Regeneron Pharmaceuticals (REGN) stake by 2.7% in Q2 2026, buying an estimated $11.6K and bringing the position to 643 shares worth $401K. The position accounts for 0.23% of the portfolio, ranked #81.

Aspire Growth Partners first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $484K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Aspire Growth Partners held 643 shares of Regeneron Pharmaceuticals worth $401K as of Q2 2026.
  • Aspire Growth Partners bought 17 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $11.6K.
  • Regeneron Pharmaceuticals made up 0.23% of Aspire Growth Partners's portfolio in Q2 2026, its #81 holding.
  • Aspire Growth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Aspire Growth Partners's Regeneron Pharmaceuticals position peaked at $484K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aspire Growth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.